Last reviewed · How we verify
NCT05222347
Immunomodulatory and Preventive Effects of Olive Leaf Tea Against COVID-19
trial testing Olive Leaf Tea in Immunomodulation in 249 participants. Completed in 5 September 2021.
4 March 2021
Quick facts
| Lead sponsor | Bezmialem Vakif University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 249 |
| Start date | 1 September 2020 |
| Primary completion | 4 March 2021 |
| Estimated completion | 5 September 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Olive Leaf Tea
Conditions studied
- Immunomodulation — all drugs for Immunomodulation →
Sponsor
Bezmialem Vakif University
Who can join
Adults 20 to 60, male only, with Immunomodulation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
During the Coronavirus Disease-2019 (COVID-19) pandemic, in addition to the current measures, boosting the immune system seems to be one of preventive measures that can be taken against COVID-19 infection. Various natural agents have been recommended to boost the immune system. The aim of this study was to investigate the possible immunomodulatory and preventive effects of Olive Leaf Tea (OLT) drinking with regards to COVID-19 infection. The study was conducted among 249 workers in a tractor factory where OLT was served. Of the 249 workers, 168 of them were OLT drinkers and 81 were not OLT drinkers. Drinking at least one cup of OLT per day for a minimum of one month was the inclusion criteria used in the study. The workers with a history of infection or vaccination of COVID-19 were excluded. Lymphocyte subsets, IL2, INF-gamma, specific IgM, and IgG levels were analyzed in all the study subjects. The results showed higher values of CD3-/CD16/56 (NK) cells, CD3+/CD16/56 (NKT) cells, total NK (NK+NKT) cells, and serum IFN-gamma and IL-2 levels in OLT drinkers as compared to the nondrinkers. These immune changes are indicative of immune defense mechanisms. Although all the OLT drinkers and non-drinkers reported no history of COVID-19, specific COVID-19 IgG levels were found positive in 60% of OLT drinkers and 38% OLT non-drinkers. There were significant negative correlations between age and NK cells, number of cigarettes smoked and NK cells, number of cigarettes smoked and TNK; and there were positive correlations between OLT drinking frequency and TNF-alpha, IL-2 and IFN-gamma. Also, serum creatinine levels in OLT non-drinkers were found significantly higher than in the OLT drinkers. In conclusion, drinking OLT may contribute fighting against COVID-19 by boosting the innate immune system.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessment of Association Between the Potential Immunomodulatory Activity and Drinking Olive Leaf Tea in the Coronavirus Disease-2019 Pandemic: An Observational Study.
Kocyigit A, Guler EM, Irban A, Kiran B, et al · · 2022 · cited 1× · PMID 36112183 · DOI 10.1089/jicm.2022.0554
Verify or expand the search:
- PubMed search for NCT05222347
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bezmialem Vakif University trials
Trials by the same sponsor.
- NCT07369297 — PULP SENSIBILITY AND MASSETER INHIBITORY REFLEX IN DIABETIC POLYNEUROPATHY · not yet recruiting
- NCT07433595 — Association Between Child and Parental Stress and Bruxism in Children Aged 8-11 Years · not yet recruiting
- NCT07443111 — Comparison of Virtual Reality-Based and Routine Preoperative Education on Surgical Anxiety and Salivary Cortisol · NA · not yet recruiting
- NCT07421349 — Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy P · not yet recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05222347 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bezmialem Vakif University
- Last refreshed: 3 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05222347.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing